[Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]

H Rodt; B Netzel; H J Kolb; R J Haas; K Wilms; C Bender-Götze; P Wernet; Gritta Janka-Schaub; H Link; W Wilmanns; S Thierfelder

[Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]

Standard

[Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]. / Rodt, H; Netzel, B; Kolb, H J; Haas, R J; Wilms, K; Bender-Götze, C; Wernet, P; Janka-Schaub, Gritta; Link, H; Wilmanns, W; Thierfelder, S.

In: Blut, Vol. 43, No. 2, 2, 1981, p. 113-118.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rodt, H, Netzel, B, Kolb, HJ, Haas, RJ, Wilms, K, Bender-Götze, C, Wernet, P, Janka-Schaub, G, Link, H, Wilmanns, W & Thierfelder, S 1981, '[Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]', Blut, vol. 43, no. 2, 2, pp. 113-118. <http://www.ncbi.nlm.nih.gov/pubmed/7020798?dopt=Citation>

APA

Rodt, H., Netzel, B., Kolb, H. J., Haas, R. J., Wilms, K., Bender-Götze, C., Wernet, P., Janka-Schaub, G., Link, H., Wilmanns, W., & Thierfelder, S. (1981). [Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]. Blut, 43(2), 113-118. [2]. http://www.ncbi.nlm.nih.gov/pubmed/7020798?dopt=Citation

Vancouver

Rodt H, Netzel B, Kolb HJ, Haas RJ, Wilms K, Bender-Götze C et al. [Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]. Blut. 1981;43(2):113-118. 2.

Bibtex

@article{df1b145e1ecc479ab5e9248d1daa7871,

title = "[Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]",

abstract = "Anti-human-thymocyte globulin (AHTZG) was applied to prevent GvHD in clinical bone marrow transplantation. AHTZG produced by absorption with several cell preparations reacted specifically with T-lymphocyte populations and was no longer inhibitory to human CFUc and bone marrow growth in diffusion chambers. Marrow grafts of 14 patients with ALL were incubated in vitro with AHTZG and transferred to the recipients conditioned with antileukemic chemotherapy and total body irradiation of 1000 rad. Ten patients were transplanted after relapse, four patients during remission. The patients tolerated the marrow without side effects and a hemopoietic engraftment was seen in 12 cases. Three patients showed signs of GvHD on the skin, two of them showed later on also manifestations in the liver. In the other cases no GvHD could be detected. Five out of 14 patients are still alive between 144 and 964 days post transplantation in remission.",

author = "H Rodt and B Netzel and Kolb, {H J} and Haas, {R J} and K Wilms and C Bender-G{\"o}tze and P Wernet and Gritta Janka-Schaub and H Link and W Wilmanns and S Thierfelder",

year = "1981",

language = "Deutsch",

volume = "43",

pages = "113--118",

number = "2",

}

RIS

TY - JOUR

T1 - [Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)]

AU - Rodt, H

AU - Netzel, B

AU - Kolb, H J

AU - Haas, R J

AU - Wilms, K

AU - Bender-Götze, C

AU - Wernet, P

AU - Janka-Schaub, Gritta

AU - Link, H

AU - Wilmanns, W

AU - Thierfelder, S

PY - 1981

Y1 - 1981

N2 - Anti-human-thymocyte globulin (AHTZG) was applied to prevent GvHD in clinical bone marrow transplantation. AHTZG produced by absorption with several cell preparations reacted specifically with T-lymphocyte populations and was no longer inhibitory to human CFUc and bone marrow growth in diffusion chambers. Marrow grafts of 14 patients with ALL were incubated in vitro with AHTZG and transferred to the recipients conditioned with antileukemic chemotherapy and total body irradiation of 1000 rad. Ten patients were transplanted after relapse, four patients during remission. The patients tolerated the marrow without side effects and a hemopoietic engraftment was seen in 12 cases. Three patients showed signs of GvHD on the skin, two of them showed later on also manifestations in the liver. In the other cases no GvHD could be detected. Five out of 14 patients are still alive between 144 and 964 days post transplantation in remission.

AB - Anti-human-thymocyte globulin (AHTZG) was applied to prevent GvHD in clinical bone marrow transplantation. AHTZG produced by absorption with several cell preparations reacted specifically with T-lymphocyte populations and was no longer inhibitory to human CFUc and bone marrow growth in diffusion chambers. Marrow grafts of 14 patients with ALL were incubated in vitro with AHTZG and transferred to the recipients conditioned with antileukemic chemotherapy and total body irradiation of 1000 rad. Ten patients were transplanted after relapse, four patients during remission. The patients tolerated the marrow without side effects and a hemopoietic engraftment was seen in 12 cases. Three patients showed signs of GvHD on the skin, two of them showed later on also manifestations in the liver. In the other cases no GvHD could be detected. Five out of 14 patients are still alive between 144 and 964 days post transplantation in remission.

M3 - SCORING: Zeitschriftenaufsatz

VL - 43

SP - 113

EP - 118

IS - 2

M1 - 2

ER -